RxDoctor Payments Data

Nader Chadda, MD

Cardiovascular Disease · Hudson, FLNPI 1225215064

Payments from drug & device makers

$94,609in general payments, 2019–2025

Across 266 payments — averaging $355.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$90K
  • Medtronic$506
  • Johnson & Johnson$469
  • Amgen$407
  • Boston Scientific$360
  • Inari Medical, Inc.$284
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$3,6004%
  • Food & beverage$6,2377%
  • Education$1,2721%
  • Other$83,50088%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,609 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,476,939
Medicare patients
677
Services billed
32,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$204,977
EntrestoSacubitril/Valsartan184$174,557
XareltoRivaroxaban63$64,052
FarxigaDapagliflozin Propanediol39$37,388
Repatha SyringeEvolocumab32$23,839
Praluent PenAlirocumab20$16,208
Repatha SureclickEvolocumab18$16,073
BrilintaTicagrelor16$14,296
JardianceEmpagliflozin12$10,398
ClopidogrelClopidogrel Bisulfate454$5,223
Varenicline Tartrate15$4,456
Midodrine Hcl41$3,080
Metoprolol Succinate186$2,174
Atorvastatin Calcium218$2,022
Ezetimibe88$1,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$204,977179 claims
NovartisEntresto$255$174,557184 claims
Johnson & JohnsonXarelto$469$64,05263 claims
AstraZenecaFarxiga, Brilinta$147$51,68455 claims
Boehringer IngelheimJardiance$234$10,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hudson

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →